Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

被引：1056

作者：

Kochenderfer, James N. ^{[1
,2
]}

Wilson, Wyndham H. ^{[3
]}

Janik, John E. ^{[3
]}

Dudley, Mark E. ^{[2
]}

Stetler-Stevenson, Maryalice ^{[4
]}

Feldman, Steven A. ^{[2
]}

Maric, Irina ^{[1
]}

Raffeld, Mark ^{[4
]}

Nathan, Debbie-Ann N. ^{[2
]}

Lanier, Brock J. ^{[2
]}

Morgan, Richard A. ^{[2
]}

Rosenberg, Steven A. ^{[2
]}

机构：

[1] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA

[2] NCI, Surg Branch, Bethesda, MD 20892 USA

[3] NCI, Metab Branch, Bethesda, MD 20892 USA

[4] NCI, Pathol Lab, Bethesda, MD 20892 USA

来源：

BLOOD | 2010年 / 116卷 / 20期

基金：

美国国家卫生研究院;

关键词：

CHIMERIC ANTIGEN RECEPTOR; HUMAN BONE-MARROW; IN-VIVO; ADOPTIVE IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; LYMPHOCYTES; ANTIBODY; DIFFERENTIATION; PERSISTENCE; EFFICACY;

D O I：

10.1182/blood-2010-04-281931

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Adoptive transfer of genetically modified T cells is an attractive approach for generating antitumor immune responses. We treated a patient with advanced follicular lymphoma by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B-cell antigen CD19. The patient's lymphoma underwent a dramatic regression, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti-CD19-CAR-transduced T cells. Blood B cells were absent for at least 39 weeks after anti-CD19-CAR-transduced T-cell infusion despite prompt recovery of other blood cell counts. Consistent with eradication of B-lineage cells, serum immunoglobulins decreased to very low levels after treatment. The prolonged and selective elimination of B-lineage cells could not be attributed to the chemotherapy that the patient received and indicated antigen-specific eradication of B-lineage cells. Adoptive transfer of anti-CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326. (Blood.2010;116(20):4099-4102)

引用

页码：4099 / 4102

页数：4

共 25 条

[21] The promise and potential pitfalls of chimeric antigen receptors [J].

Sadelain, Michel ;

Brentjens, Renier ;

Riviere, Isabelle .

CURRENT OPINION IN IMMUNOLOGY, 2009, 21 (02) :215-223

[22] Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells [J].

Till, Brian G. ;

Jensen, Michael C. ;

Wang, Jinjuan ;

Chen, Eric Y. ;

Wood, Brent L. ;

Greisman, Harvey A. ;

Qian, Xiaojun ;

James, Scott E. ;

Raubitschek, Andrew ;

Forman, Stephen J. ;

Gopal, Ajay K. ;

Pagel, John M. ;

Lindgren, Catherine G. ;

Greenberg, Philip D. ;

Riddell, Stanley R. ;

Press, Oliver W. .

BLOOD, 2008, 112 (06) :2261-2271

[23]

UCKUN FM, 1988, BLOOD, V71, P13

[24] Immunophenotypic differentiation patterns of normal Hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts [J].

van Lochem, EG ;

van der Velden, VHJ ;

Wind, HK ;

te Marvelde, JG ;

Westerdaal, NAC ;

van Dongen, JM .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2004, 60B (01) :1-13

[25] Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes [J].

Vera, Juan F. ;

Brenner, Malcolm K. ;

Dotti, Gianpietro .

CURRENT GENE THERAPY, 2009, 9 (05) :396-408

← 1 2 3 →